Receives Notice of Award from National Institutes of Health (NIH) for Third Year of Grant to Support Clinical Evaluation of TTX-MC138
Summary
The award totals nearly $871,000.We are honored that the NIH recognizes and continues to support our mission to overcome the obstacles of RNA delivery in oncology, said Michael Dudley, President and Chief Executive Officer of TransCode. Specifically, this third-year tranche of the SBIR grant will help fund the first-in-human study of our lead candidate, TTX-MC138, in patients with metastatic disease. We anticipate receiving Institutional Review Board approval shortly and commencing the clinical trial as soon as practical thereafter.TransCodes proprietary TTX platform leverages an iron oxide nanoparticle as a novel, image-guided system that it believes will safely and efficiently deliver oligonucleotides to their intended RNA targets. The Company has created a platform of drug candidates designed to target a variety of tumor types with the objective of significantly improving patient outcomes. Two of the Companys other drug candidates, TTX-siPDL1 and TTX-siLIN28B, focus on treating tumors by targeting PD-L1 and LIN28B, respectively TransCode also has two indication-agnostic programs: TTX-RIGA, an RNAbased agonist of the retinoic acid-inducible gene I designed to activate an innate immune response in cancer; and TTX-CRISPR, a CRISPR/Cas9based therapeutic platform for the repair or elimination of cancer-causing genes.